



Infectious Diseases Society of America



IDS A EXECUTIVE COMMITTEE

June 1, 2016

PRESIDENT

Johan S. Bakken, MD, PhD, FIDSA
St. Luke's ID Associates
Duluth, MN

The Honorable John McCain
Chairman
Senate Committee on Armed Services
United States Senate
218 Russell Senate Office Building
Washington, DC 20510

The Honorable Jack Reed
Ranking Member
Senate Committee on Armed Services
United States Senate
728 Hart Senate Office Building
Washington, DC 20510

PRESIDENT-ELECT

William G. Powderly, MD, FIDSA
Washington University School of Medicine
St. Louis, MO

VICE PRESIDENT

Paul G. Auwaerter, MD, MBA, FIDSA
John's Hopkins University School of Medicine
Baltimore, MD

Re: Support for Amendment #4369 to S. 2943 sponsored by Senators Cochran and Durbin

SECRETARY

Penelope H. Dennehy, MD, FIDSA
Hasbro Children's Hospital
Providence, RI

Dear Senators McCain and Reed:

TREASURER

Helen W. Boucher, MD, FIDSA
Tufts Medical Center
Boston, MA

We are writing on behalf of the Infectious Diseases Society of America and the HIV Medicine Association to express our concerns with provisions in S. 2943, The National Defense Authorization Act for Fiscal Year 2017, which would impose severe restrictions on medical research funded through the Department of Defense and impose onerous audit and contracting requirements on research grant recipients. We believe that Sections 756 and 898 of S. 2943, if enacted, would dramatically curtail infectious diseases research at the Department of Defense (DoD) in ways that would be deleterious to service members, veterans, and their families. **We urge you to eliminate these provisions by accepting Amendment #4369 to S. 2943 sponsored by Senators Cochran and Durbin.**

IMMEDIATE PAST PRESIDENT

Stephen B. Calderwood, MD, FIDSA
Massachusetts General Hospital
Boston, MA

CHIEF EXECUTIVE OFFICER

Mark Leasure
1300 Wilson Blvd, Suite 300
Arlington, VA 22209
t: (703) 299-0200 f: (703) 299-0204
info@idsociety.org
www.idsociety.org

IDS A represents more than 10,000 infectious diseases physicians and scientists devoted to research, patient care, prevention, public health and education. Within IDS A, HIVMA represents more than 5,000 researchers and clinicians on the front lines of the HIV/AIDS epidemic.

HIVMA EXECUTIVE COMMITTEE

CHAIR

Carlos del Rio, MD, FIDSA
Emory University
Atlanta, GA

DoD has significant investments in infectious diseases-related research in antimicrobial resistance, HIV infection, tuberculosis, influenza, vaccine development, and the human microbiome among others. Infectious diseases can compromise military readiness, the success of U.S. military missions and the stability and security of developing nations. The DoD infectious diseases research portfolio protects service members overseas, the health of American civilians at home, and serves as a critical component of global security efforts.

CHAIR-ELECT

Wendy Armstrong, MD, FIDSA
Emory University
Decatur, GA

VICE CHAIR

Rafael Campo, MD, FIDSA
University of Miami School of Medicine
Miami, FL

As one example, the DoD's Military HIV Research Program is a vital partner with NIH's National Institute of Allergies and Infectious Diseases in the quest to test and develop an effective vaccine to prevent HIV infection. The unique capacity of the military to conduct and manage large-scale clinical trials that are essential to successful vaccine development depends on this and other research partnerships. DoD also is partnering with the NIH and others on important research evaluating the human microbiome that includes working to improve outcomes for wounded soldiers by studying how the microorganisms they have been exposed to overseas may affect their response to available treatment options.

IMMEDIATE PAST CHAIR

Adaora Adimora, MD, MPH, FIDSA
University of North Carolina School of Medicine
Chapel Hill, NC

IDS A REPRESENTATIVE

Judith Aberg, MD, FIDSA
ICAHN School of Medicine at Mount Sinai
New York, NY

EXECUTIVE DIRECTOR

Andrea L. Weddle
1300 Wilson Blvd, Suite 300
Arlington, VA 22209
t: (703) 299-1215 f: (703) 299-8766
info@hivma.org
www.hivma.org

We respectfully ask that you reconsider the research provisions in the current bill, and accept the Cochran- Durbin amendment. At the very least, we ask that you allow for a full airing of the issues related to medical research, and a vote on the amendment, when S. 2943 reaches the Senate floor for consideration. Please contact Christine Lubinski, IDSA's VP of Global Health at clubinski@idsociety.org or Amanda Jezek, IDSA's VP of Public Policy & Government Relations at ajezek@idsociety.org if we can be a resource on this issue or others related to infectious diseases.

Sincerely yours,



Johan S. Bakken, MD, PhD, FIDSA
IDSA President



Carlos del Rio, MD, FIDSA
Chair, HIVMA Board of Directors